Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Vertex

‘Life-changing’ cystic fibrosis drugs approved for use in younger children

Campaigners welcomed the announcement by the Medicines and Healthcare Products Regulatory Agency.

The Independent UK

“We all loved Larry Carlton’s guitar, it was just magic… We were all looking for guitars with chunky necks, to try and get the sustain that he had”: Session legend Dean Parks reveals the secrets of his most iconic Steely Dan and Eric Clapton guitar parts

You can hear Parks on Josie, Haitian Divorce, Change the World, Rikki Don’t Lose That Number and innumerable other songs – here, the guitarist unpacks the gear and recording sessions that forged them

Guitar World

Best military watches for no-nonsense aesthetics, durability and practicality

Whether you’re a soldier or a civvie, these timepieces are built for any situation

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

A Middle Age Woman Copes With Cystic Fibrosis As She Prays For A Miracle

Vertexs has been present in South Africa as the young patient copes with the high cost of the medication.

Zenger

Decentralized exchange Vertex launches on Arbitrum with backing from Jane Street and Hudson River Trading

The new, self-custodial DEX will offer high-speed spot and derivatives trading.

Fortune

3 of the Best Stocks in 1 of Wall Street's Worst-Rated Industry

After years of robust growth, the biotech industry has struggled since last year due to several headwinds, including regulatory concerns, inflation, and the Fed’s aggressive rate hikes, which have sucked out speculative capital. Despite currently being one of the poorly-rated industries, investors could consider buying top-biotech stocks Gilead (GILD), Vertex…

StockNews.com

The No. 1 Biotech Stock to Buy for 2023

Biotech stock Vertex Pharmaceuticals (VRTX) outperformed its industry peers, gaining more than 30% over the past year. The company reported solid performance in the CF business and across the company in the last quarter. Moreover, VRTX is committed to delivering a diversified pipeline of transformative medicines and therapies. Hence, this…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Stocks to Buy With Rising Recession and Rate Risk

The stock market continues to be a challenging environment with rising rates a potent headwind. So far, the economy has been stable enough so that earnings growth has not contracted, but this is unlikely to persist the longer the Fed stays hawkish. This article discusses characteristics of stocks that are…

StockNews.com

3 Stocks to Ride the Bear Market Rally

Stocks could be embarking on another bear market rally despite a plethora of challenges. One factor is we are entering a seasonally bullish period of the year. Another is the bullish technical setup following the undercut and recovery of the mid-June lows. 3 stocks that investors should consider buying to…

StockNews.com

This Biotech Breakout Star is Our Growth Stock of the Week

Vertex Pharmaceuticals (VRTX) is a high-quality biotech stock that is quite cheap with impressive growth prospects. Read on to find out why it’s our growth stock of the week….

StockNews.com

3 Stocks to Buy With Rising Recession Risk, Increasing Geopolitical Tensions

Despite the bear market rally, the market is facing serious risks due to rising recession risk and increasing geopolitical tensions. Here are 3 defensive picks to help investors outperform in this tricky environment: Lockheed Martin (LMT), Vertex Pharmaceuticals (VRTX), and Elevance Health (ELVH).

StockNews.com

Daily Biotech Pulse: VistaGen's Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal's Lead Asset

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

CRISPR, 10 Years On: Learning to Rewrite the Code of Life

Ten years ago this week, Jennifer Doudna and her colleagues published the results of a test-tube experiment on bacterial genes. When the study came out in the journal Science on June 28, 2012, it did not make headline news. In fact, over the next few weeks, it did not make…

Asharq Al-Awsat

4 "Strong Buy" Biotech Stocks to Add to Your Watchlist

As the Biotech industry’s role in finding cures for chronic diseases and critical conditions is expected to keep attracting investors’ attention, it could be wise to scoop up shares of the fundamentally-strong biotech companies Vertex Pharmaceuticals (VRTX), United Therapeutics (UTHR), Amgen (AMGN), and Sino Biopharmaceutical (SBHMY) because of their solid…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

VRTX is the Growth Stock of the Week

The market is in a tough place with stubbornly high inflation, a hawkish Fed, and a slowing economy. These conditions are tough for most stocks, but pharmaceuticals are an exception. One of the top companies in the space is Vertex Pharmaceuticals (VRTX). Read on to find out why it's our…

Benzinga

Looking Into Vertex's Return On Capital Employed

According to data from Benzinga Pro, during Q1, Vertex's (NASDAQ:VERX) reported sales totaled $114.98 million. Despite a 46.73% increase in earnings, the company posted a loss of $334.00 thousand.

Dublin Live

Irish parents ‘breaking down and crying’ as children denied life changing Cystic Fibrosis medication

Sarah O’Keeffe found out that her son would not be getting the medication that would improve his life

Irish Mirror

Thousands sign petition demanding 35 kids with Cystic Fibrosis be given life-saving drug Kaftrio

'The lives of our children are at stake here, and we need to have this drug'

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What 4 Analyst Ratings Have To Say About Vertex

Analysts have provided the following ratings for Vertex (NASDAQ:VERX) within the last quarter:

Irish Mirror

Mum of boy with rare life-threatening illness devastated as miracle drug to give child a normal life pulled

"The lives of our children are being put at risk because of a financial dispute"

StockNews.com

2 Recession Stocks to Buy Right Now

Multi-decade-high inflation and aggressive Fed rate increases might push the economy into a recession. So, investors looking to mitigate a market downturn should invest in Dollar Tree (DLTR) and Vertex Pharmaceuticals (VRTX), as they could deliver stable returns because their businesses enjoy a near-inelastic demand.

Benzinga

Vertex Energy Clocks 61% Top-Line Growth In Q1

Vertex Energy Inc (NASDAQ:VTNR) reported first-quarter revenue growth of 60.6% year-over-year to $40.22 million, missing the consensus of $51.69 million. EPS loss was $(0.08) compared to $0.01 a year ago. The gross margin contracted by 466 bps to 3.8%. Vertex's operating loss increased to $(7.27) million from $(0.76) million a year ago.…

Benzinga

Recap: Vertex Q1 Earnings

Vertex (NASDAQ:VERX) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Why Vertex Pharmaceuticals Shares Are Falling

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading lower by 3.42% to $263.88 during Monday’s pre-market session after the company announced VX-880 Phase 1/2 has been placed on clinical hold by the FDA due to “a determination that there is insufficient information to support do

Benzinga

This Obscure Stock Has Outperformed Tech And EV Giants

Vertex Energy Inc (NASDAQ: VTNR) has an average trading volume of over 2 million, so it is no slouch of a stock in terms of interest.

1 2 3 4 5

People

Mangeet Kaur BounsMangeet

Jaimini DesaiJaimini Desai

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.